ResMed

“One of the most frequent questions we get is the potential return of Philips back into the U.S. device market.”

An analyst raised Philips' potential re-entry into the U.S. device market; ResMed downplayed the competitive impact, a read-through on Philips Respironics' recovery.

“incremental revenue from our VirtuOx acquisition, which we acquired in Q4 FY '25.”

ResMed's acquired home sleep apnea testing business VirtuOx contributed incremental mask/accessory revenue and had a strong quarter.

“at least 1, 2 or 3 of these wearable companies will follow Apple Watch and Samsung Galaxy Watch to develop and launch sleep apnea detection capabilities that have passed through the FDA workflow.”

ResMed points to Apple Watch sleep apnea detection as driving patients into its diagnostic funnel, a read-through on Apple's health-wearable expansion.

“was shown in Lilly's SURMOUNT-OSA study to be the best outcome in their own analysis, is one that we would encourage.”

ResMed cited Lilly's SURMOUNT-OSA study showing GLP-1 plus CPAP combination therapy as the best outcome, framing Lilly's drug as a demand tailwind rather than a threat.

“And so I think it's more likely that Zepbound or that type of a drug would be used as that third-tier versus an Apnimed which only half treats the apnea.”

ResMed's CEO frames Lilly's Zepbound (GLP-1) as displacing emerging oral drug candidates like Apnimed for third-tier sleep apnea therapy, citing its broader metabolic and cardiovascular benefits — a signal of Zepbound's expanding therapeutic reach beyond weight loss.

“Look, Lily, you know, with Lily Direct and a lot of this sort of work that they do around the GLP ones and diabetes, obesity, and now with their new IF for sleep apnea are investing in this space. They're not driving that sort of direct d two c campaign yet.”

ResMed sees Eli Lilly (via Lilly Direct and its GLP-1 franchise) as an adjacent player edging toward the sleep apnea funnel, though not yet running direct-to-consumer sleep apnea marketing, which ResMed expects to begin six to twelve months out.

“We're open to all of the other diagnostics from Knox Medical. We partner with them in Europe.”

ResMed partners with Knox Medical in Europe on home sleep apnea testing diagnostics as part of scaling capacity to triage new patients.

“ResMed products were on display in the massive Samsung booth. Samsung was touting their new Galaxy Watch's sleep apnea detection capability and illustrating the link between their Galaxy Watch ecosystem and ResMed's market-leading products for the treatment of sleep apnea.”

At CES, Samsung showcased its Galaxy Watch sleep apnea detection alongside ResMed's therapy products, illustrating a co-marketing link between the two ecosystems.

“Apple announced sleep apnea detection from the main stage as they launched the latest generation Apple Watch in September 2024.”

Apple Watch's new sleep apnea detection feature is viewed by ResMed as a demand-generation tailwind that will funnel more patients toward diagnosis and CPAP therapy over time.

“During the quarter, we announced another collaboration with the Apple Vision Pro team, with the launch of what we call the Kontor Head Strap. This is a premium accessory for the Apple Vision Pro.”

ResMed partnered with Apple to launch a premium head strap accessory for the Apple Vision Pro, extending ResMed's facial-interface expertise into consumer tech.

“So late during our Q2 on December 20th, Eli Lilly gained FDA approval for the use of Zepbound a GLP-1, in patients with obesity and moderate to severe sleep apnea with a reduced calorie diet and physical exercise.”

Eli Lilly's Zepbound received FDA approval for obstructive sleep apnea in December 2024; ResMed frames GLP-1 drugs as complementary rather than substitutive to CPAP therapy, citing trial data favoring combination therapy.

“how would you say ResMed is buffered from a potentially more price-sensitive environment if and when Philips returns to the market?”

An analyst asks how ResMed is positioned against Philips's anticipated return to the CPAP device market following its multi-year, recall-driven absence from U.S. device sales.